GC Pharma and Kyowa Kirin are fiercely competing for the lead in the neutropenia treatment market in Korea. At the end of last year, GC Pharma’s Neulapeg had risen to the lead for the first time in 7 years, but Kyowa Kirin has again taken over the lead with Neulasta. The addition of Boryung’s sales power to the products is affecting the sales rank of the two drugs in Korea.

According to the pharmaceutical market research institution IQVIQ, Neulasta sold the most and raised ₩6.5 billion in sales in the neutropenia treatment market in Q1 this year. Rising 4.9% YoY, Neulasta took back the lead that it had lost to Neulapeg in Q4 last year.

Neutropenia treatments prevent cancer patients f